Fulcrum Therapeutics, Inc. (FULC)
3.86
+0.02
(+0.52%)
USD |
NASDAQ |
Aug 25, 16:00
3.83
-0.03
(-0.78%)
After-Hours: 19:59
Fulcrum Therapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 99.50% |
| March 31, 2024 | |
| December 31, 2023 | 41.68% |
| September 30, 2023 | 34.12% |
| June 30, 2023 | 31.82% |
| March 31, 2023 | -91.86% |
| December 31, 2022 | 13.72% |
| September 30, 2022 | 49.28% |
| June 30, 2022 | 62.81% |
| Date | Value |
|---|---|
| March 31, 2022 | 79.32% |
| December 31, 2021 | 87.72% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 82.65% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 28.13% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 88.57% |
| CNBX Pharmaceuticals, Inc. | -- |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 95.92% |
| Definium Therapeutics, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -30.23% |
| Return on Assets | -28.70% |
| Return on Invested Capital | -29.56% |
| Return on Net Operating Assets | -914.1% |